{"id":105866,"date":"2026-06-11T19:22:14","date_gmt":"2026-06-11T19:22:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/105866\/"},"modified":"2026-06-11T19:22:14","modified_gmt":"2026-06-11T19:22:14","slug":"novo-nordisk-flags-it-security-incident","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/105866\/","title":{"rendered":"Novo Nordisk flags IT security incident"},"content":{"rendered":"

!- – Start GPT Tag – ->
\n
\n
\n<!- – End GPT Tag – -> <\/p>\n

<\/p>\n

\"PharmaLive\"<\/a> <\/p>\n

\t\t
\n
\n <\/p>\n

\t\t\t\t\t\"alert\"<\/a><\/p>\n

Today Novo Nordisk issued an alert about an IT security incident that involved unauthorized access to internal IT systems. According to the company\u2019s incident update<\/a>, certain patient personal data from trial participation was compromised. The company stated that this information is not directly linked to any patients by name or other direct identifiers. \u201cInformation about identity would therefore require access to underlying information, identifying patients by name etc. This information was not exposed. We therefore do not consider the incident to enable any third party to identify participants in our clinical trials,\u201d according to Novo Nordisk.\u00a0<\/p>\n

\u201cAs part of our response, multiple security measures have been taken, including temporarily taking certain internal IT systems offline to protect our environment. We are working to bring the affected systems back online in a controlled and safe manner; however, we acknowledge this process takes time,\u201d Novo Nordisk stated in its alert. \u201cWhile our investigation and response are ongoing, we have discovered that certain non-public data, including personal data, were copied externally without authorization. We are informing the impacted parties as appropriate.\u201d<\/p>\n

Novo Nordisk stated that it does not believe that there are any current risks to patients but has asked them to remain \u201cvigilant\u201d and to report anything unusual to the company that they believe may be related to this breach.\u00a0<\/p>\n

Read the latest incident update from Novo Nordisk.\u00a0<\/a><\/p>\n

June 11, 2026\/by Administrator<\/a>Tags: clinical trials<\/a>, cybersecurity<\/a>, IT security<\/a>, Novo Nordisk<\/a>, patient information<\/a>, personal data<\/a><\/p>\n

\t\t\t\t\t\thttps:\/\/www.pharmalive.com\/wp-content\/uploads\/2024\/12\/alert.jpg
\n\t\t\t\t\t\t600
\n\t\t\t\t\t\t600<\/p>\n

\t\t\t\t\t\tAdministrator<\/p>\n

\t\t\t\t\t\t\thttps:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/Pharmalive_4c-300×37.png<\/p>\n

\t\t\t\tAdministrator2026-06-11 14:50:512026-06-11 14:50:51Novo Nordisk flags IT security incident<\/p>\n

\t\tTakeda\u2019s AI-designed pill bests BMS\u2019 Sotyktu in head-to-head psoriasis …\"Takeda\"<\/a>\t\t\t<\/p>\n

Scroll to top<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"!- – Start GPT Tag – -> <!- – End GPT Tag – -> …\n","protected":false},"author":2,"featured_media":105867,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[15044,3499,53842,272,53843,41616],"class_list":["post-105866","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-clinical-trials","tag-cybersecurity","tag-it-security","tag-novo-nordisk","tag-patient-information","tag-personal-data"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116733106143438693","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/105866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=105866"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/105866\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/105867"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=105866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=105866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=105866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}